comparemela.com

Latest Breaking News On - Topline results expected - Page 3 : comparemela.com

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023. | April 4, 2023

United statesItaly generalJulia neugebauerTim demuthEamonn nolanThomas biegiAmerican society of hematologyGerman lymphoma associationDrug administrationConstellation pharmaceuticals incXencor incUs oncology networkExchange commissionSys completes enrollmentTopline results expectedChief research

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topli

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa.

United statesItaly generalJulia neugebauerThomas biegiEamonn nolanTim demuthUs oncology networkDrug administrationDistribution servicesGerman lymphoma associationXencor incExchange commissionAmerican society of hematologyConstellation pharmaceuticals incSys completes enrollmentTopline results expected

EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible .

United statesItaly generalJulia neugebauerEamonn nolanTim demuthThomas biegiDistribution servicesTradegate exchangeNews serviceConstellation pharmaceuticals incAmerican society of hematologyXencor incUs oncology networkExchange commissionDrug administrationGerman lymphoma association

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Baden wübergSwitzerland generalSouth africaAnne donohoeSophia bashfordHans erikssonDevelco pharmaKetabon programBrain healthHolding gmbHmnc brain healthOral prolonged release ketamineTopline results expectedTreatment resistant depressionChief medical officerDepression rating scale

HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) HMNC Brain Health ("HMNC' or the "Company"), a global clinical stage biopharmaceutical

Switzerland generalBaden wübergSouth africaDevelco pharmaHans erikssonBrain healthKetabon programHolding gmbTopline results expectedTreatment resistant depressionChief medical officerDepression rating scaleMajor depressive disorderMiddle east

vimarsana © 2020. All Rights Reserved.